Iqvia price target lowered to $258 from $266 at Guggenheim

Guggenheim analyst Sandy Draper lowered the firm’s price target on Iqvia to $258 from $266 and keeps a Buy rating on the shares. The company reported what the firm would characterize as an "in-line" quarter, the analyst tells investors. The CRO space may lack a significant near-term catalyst to expand multiples, but Guggenheim thinks downside risk is limited.